Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GBSNASDAQ:KRMDNASDAQ:STIMNASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBSGBS$2.20+0.9%$1.83$0.36▼$2.89$32.76M1.32955,325 shs52,371 shsKRMDKORU Medical Systems$2.70-17.7%$3.99$2.04▼$5.05$123.76M0.74136,217 shs347,823 shsSTIMNeuronetics$4.41-4.8%$3.38$0.52▼$5.92$133.84M2.07588,940 shs1.26 million shsTLSITriSalus Life Sciences$5.30$5.28$3.50▼$10.42$161.61M0.4834,541 shs17,845 shs7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBSGBS-1.80%+5.06%+2.83%+32.93%-53.12%KRMDKORU Medical Systems+5.47%+1.86%-29.46%-25.45%+56.19%STIMNeuronetics+1.98%-14.58%+19.95%+299.14%+7.42%TLSITriSalus Life Sciences+4.13%-7.83%-5.02%+33.50%-43.38%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGBSGBSN/AN/AN/AN/AN/AN/AN/AN/AKRMDKORU Medical Systems2.7927 of 5 stars3.53.00.00.02.32.50.6STIMNeuronetics1.5143 of 5 stars2.32.00.00.03.01.70.6TLSITriSalus Life Sciences3.3525 of 5 stars3.63.00.00.03.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBSGBS 0.00N/AN/AN/AKRMDKORU Medical Systems 3.00Buy$4.7074.07% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5024.72% UpsideTLSITriSalus Life Sciences 3.20Buy$11.56118.16% UpsideCurrent Analyst Ratings BreakdownLatest GBS, TLSI, KRMD, and STIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.002/14/2025KRMDKORU Medical SystemsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$4.50 ➝ $4.502/13/2025TLSITriSalus Life SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.001/24/2025TLSITriSalus Life SciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.001/17/2025KRMDKORU Medical SystemsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.001/14/2025KRMDKORU Medical SystemsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.0012/17/2024TLSITriSalus Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBSGBS$440K74.45N/AN/A$0.44 per share5.00KRMDKORU Medical Systems$31.99M3.87N/AN/A$0.45 per share6.00STIMNeuronetics$74.89M1.79N/AN/A$1.18 per share3.74TLSITriSalus Life Sciences$26.89M6.01N/AN/A($0.98) per share-5.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBSGBS-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/AKRMDKORU Medical Systems-$13.74M-$0.25N/AN/AN/A-37.42%-24.60%-16.87%N/ASTIMNeuronetics-$30.19M-$1.37N/AN/AN/A-50.09%-141.24%-32.77%5/6/2025 (Estimated)TLSITriSalus Life Sciences-$59.04M-$2.49N/AN/AN/A-206.24%N/A-236.83%3/27/2025 (Confirmed)Latest GBS, TLSI, KRMD, and STIM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/7/2025N/ATLSITriSalus Life Sciences-$0.35N/AN/AN/AN/AN/A3/27/2025N/ATLSITriSalus Life Sciences-$0.35N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBSGBSN/AN/AN/AN/AN/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBSGBSN/A2.332.33KRMDKORU Medical Systems0.012.992.37STIMNeuronetics4.903.162.87TLSITriSalus Life SciencesN/A2.402.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBSGBS2.79%KRMDKORU Medical Systems58.60%STIMNeuronetics53.59%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipGBSGBS0.27%KRMDKORU Medical Systems25.60%STIMNeuronetics9.80%TLSITriSalus Life Sciences32.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGBSGBS714.89 million14.85 millionNot OptionableKRMDKORU Medical Systems8045.84 million34.10 millionOptionableSTIMNeuronetics18030.35 million27.37 millionOptionableTLSITriSalus Life Sciences10630.49 million20.49 millionNot OptionableGBS, TLSI, KRMD, and STIM HeadlinesRecent News About These CompaniesShort Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Expands By 75.3%March 4, 2025 | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $11.56 Consensus Price Target from BrokeragesMarch 3, 2025 | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Large Increase in Short InterestMarch 2, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from AnalystsFebruary 28, 2025 | marketbeat.com3 Stocks With Robust Growth Outlooks Insiders Are Buying (TLSI)February 19, 2025 | insidertrades.comTriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Lake Street CapitalFebruary 13, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $33,900.00 in StockFebruary 7, 2025 | insidertrades.comTrisalus Life Sciences CFO buys $33,900 in common stockFebruary 6, 2025 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Purchases 5,030 SharesFebruary 1, 2025 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Buys 4,826 SharesJanuary 30, 2025 | insidertrades.comTriSalus Life Sciences: Strong Q4 2024 Performance and Promising 2025 Outlook Drive Buy RatingJanuary 25, 2025 | markets.businessinsider.comTriSalus reports 59% annual revenue growth in 2024January 23, 2025 | msn.comTriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference CallJanuary 23, 2025 | stockhouse.comTriSalus Life Sciences Prelim. Q4 Revenue SurgesJanuary 23, 2025 | markets.businessinsider.comTriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are CutDecember 24, 2024 | seekingalpha.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Equity Ab Frankenius Acquires 62,972 SharesDecember 20, 2024 | insidertrades.comMats Wahlstrom Acquires 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockNovember 26, 2024 | insidertrades.comTriSalus Life Sciences price target lowered to $11 from $12 at CanaccordNovember 16, 2024 | markets.businessinsider.comTriSalus Life Sciences: Strong Growth and Strategic Partnerships Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comRoth MKM Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)November 15, 2024 | markets.businessinsider.comTriSalus Life Sciences sees FY25 revenue growth ‘more than 50%’November 15, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGBS, TLSI, KRMD, and STIM Company DescriptionsGBS NYSE:GBS$2.20 +0.02 (+0.92%) As of 03/12/2025GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.KORU Medical Systems NASDAQ:KRMD$2.70 -0.58 (-17.68%) Closing price 04:00 PM EasternExtended Trading$2.74 +0.04 (+1.67%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.Neuronetics NASDAQ:STIM$4.41 -0.22 (-4.75%) Closing price 04:00 PM EasternExtended Trading$4.42 +0.00 (+0.11%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.TriSalus Life Sciences NASDAQ:TLSI$5.28 -0.02 (-0.38%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Market Overreacts, But Guidewire’s Growth Story Remains Strong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
